Tislelizumab Receives Israeli Approval in Unresectable or Metastatic ESCC - OncLive
The Israeli Ministry of Health approved tislelizumab-jsgr (Tevimbra) for treating adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy. The approval is based on the phase 3 RATIONALE 302 trial, which showed tislelizumab significantly improved median overall survival compared to chemotherapy.
Related Clinical Trials
Reference News
Tislelizumab Receives Israeli Approval in Unresectable or Metastatic ESCC - OncLive
The Israeli Ministry of Health approved tislelizumab-jsgr (Tevimbra) for treating adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy. The approval is based on the phase 3 RATIONALE 302 trial, which showed tislelizumab significantly improved median overall survival compared to chemotherapy.